Trexquant Investment LP purchased a new stake in La Jolla Pharmaceutical (NASDAQ:LJPC) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 26,682 shares of the biopharmaceutical company’s stock, valued at approximately $795,000. Trexquant Investment LP owned about 0.10% of La Jolla Pharmaceutical at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC acquired a new position in shares of La Jolla Pharmaceutical in the 1st quarter valued at approximately $134,000. Geode Capital Management LLC grew its position in shares of La Jolla Pharmaceutical by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 155,954 shares of the biopharmaceutical company’s stock valued at $5,018,000 after purchasing an additional 6,375 shares during the period. Calton & Associates Inc. acquired a new position in shares of La Jolla Pharmaceutical in the 4th quarter valued at approximately $266,000. MetLife Investment Advisors LLC acquired a new position in shares of La Jolla Pharmaceutical in the 4th quarter valued at approximately $276,000. Finally, Hudson Bay Capital Management LP grew its position in shares of La Jolla Pharmaceutical by 50.0% in the 4th quarter. Hudson Bay Capital Management LP now owns 30,000 shares of the biopharmaceutical company’s stock valued at $965,000 after purchasing an additional 10,000 shares during the period.

In other news, major shareholder Perceptive Advisors Llc purchased 700,000 shares of La Jolla Pharmaceutical stock in a transaction on Thursday, March 15th. The stock was purchased at an average price of $29.50 per share, with a total value of $20,650,000.00. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Kevin C. Tang purchased 508,474 shares of La Jolla Pharmaceutical stock in a transaction on Thursday, March 15th. The shares were purchased at an average cost of $29.50 per share, with a total value of $14,999,983.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have acquired 1,369,474 shares of company stock valued at $40,759,863. Insiders own 25.47% of the company’s stock.

Shares of La Jolla Pharmaceutical opened at $33.27 on Thursday, according to Marketbeat Ratings. La Jolla Pharmaceutical has a 52-week low of $32.17 and a 52-week high of $32.82.

La Jolla Pharmaceutical (NASDAQ:LJPC) last released its quarterly earnings results on Thursday, May 10th. The biopharmaceutical company reported ($2.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.74). The business had revenue of $0.81 million during the quarter. research analysts predict that La Jolla Pharmaceutical will post -6.52 EPS for the current fiscal year.

Several brokerages recently issued reports on LJPC. Zacks Investment Research lowered La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Thursday. HC Wainwright reiterated a “buy” rating and issued a $83.00 price objective (up from $72.00) on shares of La Jolla Pharmaceutical in a research report on Friday, May 11th. ValuEngine upgraded La Jolla Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Wednesday, May 2nd. Finally, BidaskClub upgraded La Jolla Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Tuesday, March 13th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $55.86.

La Jolla Pharmaceutical Profile

La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. It offers GIAPREZA, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock.

Institutional Ownership by Quarter for La Jolla Pharmaceutical (NASDAQ:LJPC)

Receive News & Ratings for La Jolla Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for La Jolla Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.